logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
M

Melissa L. Johnson

university of london

65H-index
835Paper Count
2.3WCitation Count
Published Papers 136
Publication Date
logo
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation
errAnnals of Oncology
IF65.4
err2026-08-06
err0
PREAI
errH.A. Wakelee; M-J. Ahn; J. Bradley; S. Popat; K. Kelly; A-M. Baird; O. Ozyilkan; J. Yu; S.Y. Lee; N. Yanagitani; M. Johnson; A. Sánchez-Hernández; A. Szczesna; K. Cuppens; E. Yao; C. Parsons; C. Matheny; Z. Zhang; M.N. White; J.J. Hsu
errShare
errSave
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer
errBritish Journal of Cancer
IF6.8
err2026-04-03
err0
errOAAI
errMelissa L. Johnson; Giulia Fabbri; Carmela Ciardullo; Judy S. Wang; Gerald S. Falchook; Suzanne Jones; Donald Strickland; Jacob Sands; Carl M. Gay; Robert J. Cardnell; Luis Tobalina; Sophie E. Willis; Jaime Rodriguez-Canales; Myria Nikolaou; Emma V. Jones; Stein Schalkwijk; Liz Sainsbury; Alexander MacDonald; Philip Overend; Caroline Kennedy; J. Elizabeth Pease; Philip Szekeres; Jan Cosaert; Howard Burris; Lauren A. Byers
errShare
errSave
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
errThe Lancet Oncology
IF0
err2026-03-30
err0
PREAI
errMelissa L Johnson; Manish R Patel; Gerald S Falchook; Takafumi Koyama; Martin Gutierrez; Mark M Awad; Sarina A Piha-Paul; Claire F Friedman; Taroh Satoh; Naoko Okamoto; Jasmeet Singh; Naoto Yoshizuka; Hillarie Plessner Windish; Meng Qian; Brittany P Tran; Toshihiko Doi
errShare
errSave
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1
errLung Cancer
IF4.4
err2026-02-11
err0
errOAAI
errJarushka Naidoo; Solange Peters; Yotsawaj Runglodvatana; Jacky Yu-Chung Li; Chin Heng Fong; Gwo Fuang Ho; Soon Hin How; Jitlada Juengsamarn; Julie R Graham; Neyssa Marina; Thao Dang; Deepa Patel; Sasha Han; Candy Bermingham; Melissa L Johnson
errShare
errSave
TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer
errClinical Lung Cancer
IF3.3
err2026-01-26
err0
PREAI
errLuis G. Paz-Ares; Kenneth John O'Byrne; Melissa L. Johnson; Martin Reck; Nicolas Girard; Hidetoshi Hayashi; Caicun Zhou; Vishwanath Suresh Gharpure; Radhika Pisupati; Misena Pacius; Neal E. Ready
errShare
errSave
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors
errFuture Oncology
IF2.6
err2026-01-01
err0
errOAAI
errDumbrava, Ecaterina; Minchom, Anna; Henry, Jason; Johnson, Melissa; Sommerhalder, David; Merchan, Jaime; Heist, Rebecca; Cabanas, Elena Garralda; Cotreau, Monette; Goenaga, Anne-Laure; Burzyn, Dalia; Makris, Lukas; Culm, Kerry; Abbadessa, Giovanni
errShare
errSave
Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer
errTargeted Oncology
IF4
err2025-11-10
err0
errOAAI
errMelissa L. Johnson; Shaker R. Dakhil; J. Thaddeus Beck; Ahad Sadiq; Smitha Menon; Ganesh M. Mugundu; Juliann Chmielecki; David R. Spigel
errShare
errSave
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
errOncology and Therapy
IF3.2
err2025-10-11
err0
errOAAI
errBalazs Halmos; Narjust Florez; Sarah Goldberg; Wade Iams; Xiuning Le; Ticiana Leal; Danny Nguyen; Luis E. Raez; Jonathan W. Riess; Joshua Sabari; David Bjork; Nichelle Stigger; Yichuan Xia; Paul Cifuentes; Denise D’Andrea; Farah Shanoon; Andy L. Johnson; Melissa L. Johnson
errShare
errSave
A Response to the Letter to the Editor: “POSEIDON’s Missing Piece: Unanswered Questions on PFS Data in High-Risk Subgroups”
errJournal of Thoracic Oncology
IF20.8
err2025-06-06
err0
PREAI
errSolange Peters; Byoung Chul Cho; Melissa L. Johnson
errShare
errSave
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report
errJournal of Thoracic Oncology
IF20.8
err2025-06-04
err0
errOAAI
errGregory J. Riely; Myung-Ju Ahn; Jeffrey M. Clarke; Ibiayi Dagogo-Jack; Raymond Esper; Enriqueta Felip; Francesco Gelsomino; Jonathan W. Goldman; Maen Hussein; Melissa Johnson; Kristen A. Marrone; Daniel Morgensztern; Ernest Nadal; Marcelo V. Negrao; Michael Offin; Mariano Provencio; Suresh S. Ramalingam; Logan Roof; Rachel E. Sanborn; Egbert F. Smit; Anne Tsao; Tiziana Usari; Ann Alcasid; Keith Wilner; Svitlana Tonkovyd; Xiaosong Zhang; Bruce E. Johnson
errShare
errSave
A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors
errTargeted Oncology
IF4
err2025-06-04
err0
PREAI
errLillian L. Siu; David S. Hong; Wolf-Dietrich Döcke; Reimo Tetzner; Mark Trautwein; Charles Phelps; Joerg Willuda; Xiang Qing Yu; Hendrik Nogai; Melissa Johnson; Boon Cher Goh
errShare
errSave
A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect level
errBRITISH JOURNAL OF CLINICAL PHARMACOLOGY
IF3
err2025-04-27
err0
PREAI
errLin Yuan; Meghana Kulkarni; Evan Chiswick; Cheryl Koh; Peter Sandy; Salah Nabhan; Woody Sherman; Melissa Johnson; Judy Wang; Gerald Falchook; Jennifer Johnson; Christopher Winter; Humphrey Gardner; Arijit Chakravarty; Madison Stoddard
errShare
errSave
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
errCELL REPORTS MEDICINE
IF10.6
err2025-04-01
err0
errOAAI
errLopez, Juanita S.; Milhem, Mohammed; Butler, Marcus O.; Thistlethwaite, Fiona; Van Tine, Brian A.; D'Angelo, Sandra P.; Johnson, Melissa L.; Sato, Takami; Arkenau, Hendrik-Tobias; Edukulla, Ramakrishna; Wustner, Jason; Marshall, Shannon; Rodon, Jordi
errShare
errSave
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
errFUTURE ONCOLOGY
IF2.6
err2025-03-01
err0
errOAAI
errde Langen, Adrianus Johannes; Johnson, Melissa L.; Mazieres, Julien; Dingemans, Anne-Marie C.; Mountzios, Giannis; Pless, Miklos; Wolf, Juergen; Schuler, Martin; Lena, Herve; Skoulidis, Ferdinandos; Yoneshima, Yasuto; Kim, Sang-We; Linardou, Helena; Novello, Silvia; van der Wekken, Anthonie J.; Chen, Yuanbin; Peters, Solange; Felip, Enriqueta; Solomon, Benjamin J.; Ramalingam, Suresh S.; Dooms, Christophe; Lindsay, Colin R.; Ferreira, Carlos Gil; Blais, Normand; Obiozor, Cynthia C.; Wang, Yang; Mehta, Bhakti; Varrieur, Tracy; Ngarmchamnanrith, Gataree; Stollenwerk, Bjoern; Waterhouse, David; Paz-Ares, Luis
errShare
errSave
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma
errINVESTIGATIONAL NEW DRUGS
IF2.7
err2025-03-01
err0
PREAI
errJohnson, Melissa; Hong, David; Brana, Irene; Schoffski, Patrick; Galvao, Vladimir; Rangwala, Fatima; Ma, Bo; Hernandez, Robert; Kamat, Asha; Kato, Kazunobu; Schreiber, Taylor H.; Pandite, Lini; Siu, Lillian L.
errShare
errSave
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial
errADVANCES IN THERAPY
IF4
err2025-03-01
err0
errOAAI
errHummel, Horst-Dieter; Ahn, Myung-Ju; Blackhall, Fiona; Reck, Martin; Akamatsu, Hiroaki; Ramalingam, Suresh S.; Borghaei, Hossein; Johnson, Melissa; Dirnberger, Franziska; Cocks, Kim; Huang, Shuang; Mukherjee, Sujoy; Paz-Ares, Luis
errShare
errSave
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)( vol 197 , 107960 , 2024)
errLUNG CANCER
IF4.4
err2025-02-01
err0
errOAAI
errJohnson, Melissa; Younan, Diana; Kent, Shia T.; Frias, Marco Mesa; Brookhart, M. Alan; Balasubramanian, Akhila; Spira, Alexander
errShare
errSave
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
errMOLECULAR CANCER THERAPEUTICS
IF5.5
err2024-12-31
err0
errOAAI
errJohnson, Melissa L.; Wolf, Beni B.; Wang, Judy S.; Philipovskiy, Alexander; Shapiro, Geoffrey I.; Bockorny, Bruno; Guo, Wei; Shen, Jinshan; Jen, Kai Yu; Lerose, Marybeth; Hunter, Tamieka Lauz; Padval, Mahesh; Schmidt-Kittler, Oleg; Bhatia, Namrata; Dubey, Sarita; Suchomel, Julia; Bendell, Johanna C.; Jauhari, Shekeab; Eng-Wong, Jennifer; Lin, Jessica J.
errShare
errSave
A Podcast Discussion on the Intracranial Efficacy of Antibody-Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
errONCOLOGY AND THERAPY
IF3.2
err2024-12-18
err0
errOAAI
errJohnson, Melissa L.; Lin, Jessica J.; Boire, Adrienne; Khandekar, Melin J.; Yu, Helena A.
errShare
errSave
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC
errFRONTIERS IN ONCOLOGY
IF3.3
err2024-12-05
err0
errOAAI
errShiller, Michelle; Johnson, Melissa; Auber, Robert; Patel, Sandip Pravin
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
M
Marc Ladanyi
H-index: 204 · Papers: 2.5K
G
George D. Yancopoulos
H-index: 203 · Papers: 943
D
David Cella
H-index: 184 · Papers: 1.9K
P
Pasi A. Jänne
H-index: 163 · Papers: 2.3K
F
F. Stephen Hodi
H-index: 156 · Papers: 1.5K
View more